Hybrid ribozymes as therapeutics

Scientists have long toyed with the idea of putting to work a special class of biological catalysts, called ribozymes, as therapeutic agents. These molecular scissors would harness the activities of overly active genes that contribute to diseases like cancer by cutting their immediate products, messenger RNAs, into unusable pieces. The advantage of this approach, is that these molecules can be made to recognize very specific targets. This is reported in this month issue of EMBO reports.

Contact:
Ellen Peerenboom
ellen.peerenboom@embo.org
49-622-188-91108
European Molecular Biology Laboratory

Message posted by: Wouter Kalle